APLS Apellis Pharmaceuticals

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

Apellis Pharmaceuticals to Host Conference Call on November 1, 2023, to Discuss Third Quarter 2023 Financial Results

WALTHAM, Mass., Oct. 25, 2023 (GLOBE NEWSWIRE) -- , Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its third quarter 2023 financial results on Wednesday, November 1, 2023, at 8:00 a.m. ET.

To access the live call by phone, please pre-register for the call . A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s . A replay of the webcast will be available for 90 days following the event.

About Apellis 

Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first-ever therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit or follow us on and .

Investor Contact:

Meredith Kaya



617.599.8178



EN
25/10/2023

Underlying

APLSApellis Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Apellis Pharmaceuticals

Wedbush Research
  • Wedbush Research
DPZ DOMINO'S PIZZA INC.
SHAK SHAKE SHACK INC. CLASS A
DEI DOUGLAS EMMETT INC
HPP HUDSON PACIFIC PROPERTIES INC.
XENE XENON PHARMACEUTICALS INC
WING WINGSTOP INC.
WEN WENDY'S COMPANY
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
TXRH TEXAS ROADHOUSE INC.
TSLA TESLA INC
TRNO TERRENO REALTY CORPORATION
STKS ONE GROUP HOSPITALITY
STAG STAG INDUSTRIAL INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBUX STARBUCKS CORPORATION
PZZA PAPA JOHN'S INTERNATIONAL INC.
PEGA PEGASYSTEMS INC.
OFC CORPORATE OFFICE PROPERTIES TRUST
MCD MCDONALD'S CORPORATION
JACK JACK IN THE BOX INC.
IMAX IMAX CORPORATION
EGP EASTGROUP PROPERTIES INC.
EAT BRINKER INTERNATIONAL INC.
DIN DINE BRANDS GLOBAL INC.
DENN DENNY'S CORPORATION
CTMX CYTOMX THERAPEUTICS INC.
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CAKE CHEESECAKE FACTORY INCORPORATED
BXP BOSTON PROPERTIES INC.
BIIB BIOGEN INC.
ARDX ARDELYX INC
BJRI BJ'S RESTAURANTS INC.
FRX_CN FENNEC PHARMACEUTICALS
CMG CHIPOTLE MEXICAN GRILL INC.
DRI DARDEN RESTAURANTS INC.
WVE WAVE LIFE SCIENCES
PLYM PLYMOUTH INDUSTRIAL REIT INC.
MRSN MERSANA THERAPEUTICS
ISR ISORAY
AMZN AMAZON.COM INC.
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
SRRK SCHOLAR ROCK HOLDING CORPORATION
YMAB Y-MABS THERAPEUTICS
TVTX TRAVERE THERAPEUTICS INC
PLTK PLAYTIKA HOLDING
RBLX ROBLOX
TNGX TANGO THERAPEUTICS
VERA INC
BROS VERA THERAPEUTICS INC
STRW DUTCH BROS INC
CAVA STRAWBERRY FIELDS REIT INC.
JBIO CAVA GROUP INC
JADE BIOSCIENCES
INC.
05/12/25 May 12, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
BIIB BIOGEN INC.
ARDX ARDELYX INC
APLS APELLIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
VERA VERA THERAPEUTICS INC
JBIO JADE BIOSCIENCES
INC.
05/12/25 May 12, 2025 1 EN
Dylan Shindler ... (+2)
  • Dylan Shindler
  • Laura Chico
APLS APELLIS PHARMACEUTICALS
05/07/25 May 7, 2025 1 EN
 PRESS RELEASE
Free
APLS Apellis Pharmac...

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results

Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results Generated $166.8 million in 1Q 2025 revenues, including $149.9 million in U.S. net product salesSYFOVRE® (pegcetacoplan injection) injection demand grew 4% quarter-over-quarter, with U.S. net product revenue of $130.2 million Increase in demand offset by inventory dynamics and funding shortages at co-pay assistance programs Received U.S. FDA filing acceptance of supplemental new drug application (sNDA) with Priority Review designation for EMPAVELI for treatment of C3G and primary IC-MPGNOn track to initiate two pivotal tri...

May 7, 2025 1 EN
Wedbush Research
  • Wedbush Research
GEO GEO GROUP INC. (THE)
WDC WESTERN DIGITAL CORPORATION
VYGR VOYAGER THERAPEUTICS INC.
VRNS VARONIS SYSTEMS INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBRA SABRA HEALTH CARE REIT INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
QLYS QUALYS INC.
PSTG PURE STORAGE INC. CLASS A
OHI OMEGA HEALTHCARE INVESTORS INC.
O REALTY INCOME CORPORATION
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NHI NATIONAL HEALTH INVESTORS INC.
NCMI NATIONAL CINEMEDIA INC.
MU MICRON TECHNOLOGY INC.
LTC LTC PROPERTIES INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
CTRE CARETRUST REIT INC
BIIB BIOGEN INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
EA ELECTRONIC ARTS INC.
PTGX PROTAGONIST THERAPEUTICS
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
UBER UBER TECHNOLOGIES INC.
DDOG DATADOG INC CLASS A
SMCI SUPER MICRO COMPUTER
IDYA INC.
ACET IDEAYA BIOSCIENCES
CRSR ADICET BIO INC
KROS CORSAIR GAMING
TVTX KEROS THERAPEUTICS
DASH TRAVERE THERAPEUTICS INC
DAWN DOORDASH
STX DAY ONE BIOPHARMACEUTICALS INC
VERA SEAGATE TECHNOLOGY HLDGS PLC
RIVN VERA THERAPEUTICS INC
GFS RIVIAN AUTOMOTIVE INC
JBIO GLOBALFOUNDRIES INC
JADE BIOSCIENCES
INC.
05/07/25 May 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch